N. Mitsiades

发表

Integrative genomic profiling of human prostate cancer.

C. Sander, H. Hieronymus, W. Gerald, 2010, Cancer cell.

Inhibition of Hsp90 attenuates inflammation in endotoxin‐induced uveitis

Joan W. Miller, E. Gragoudas, N. Mitsiades, 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.

I. Stamenkovic, N. Mitsiades, V. Poulaki, 2000, Cancer research.

Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer.

A. Chinnaiyan, A. Shojaie, G. Michailidis, 2014, Journal of proteome research.

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity

K. Anderson, N. Munshi, D. McMillin, 2010, Nature Medicine.

Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells

K. Anderson, N. Munshi, N. Mitsiades, 2003, Oncogene.

Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.

N. Mitsiades, C. Mitsiades, A. Ashkenazi, 2002, The American journal of pathology.

Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies.

C. Mantzoros, N. Mitsiades, T. Kelesidis, 2007, The Journal of clinical endocrinology and metabolism.

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

D. Neuberg, K. Anderson, N. Munshi, 2002, Cancer research.

Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy.

Joan W. Miller, E. Gragoudas, N. Mitsiades, 2009, Investigative ophthalmology & visual science.

Role of 4 Integrin ( CD 49 d ) in the Pathogenesis of Diabetic Retinopathy

Joan W. Miller, E. Gragoudas, N. Mitsiades, 2009 .

Nuclear Factor-κB p65 Mediates Tumor Necrosis Factor α-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein

K. Anderson, N. Munshi, P. Richardson, 2003 .

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

K. Anderson, N. Munshi, P. Richardson, 2003, Blood.

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

K. Anderson, T. Libermann, N. Munshi, 2003, Blood.

Cognitive effects of hormonal therapy in older adults.

C. Gross, D. Correa, N. Mitsiades, 2008, Seminars in oncology.

miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.

K. Rajapakshe, C. Coarfa, B. O’Malley, 2015, Molecular endocrinology.

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.

K. Anderson, N. Munshi, P. Atadja, 2003, Blood.

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

K. Anderson, N. Munshi, P. Richardson, 2002, Cancer research.

Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.

N. Mitsiades, C. Mitsiades, G. Voutsinas, 2009, Endocrine-related cancer.

Circulating Adiponectin Levels and Expression of Adiponectin Receptors in Relation to Lung Cancer: Two Case-Control Studies

C. Mantzoros, N. Mitsiades, E. Petridou, 2008, Oncology.

P2X7 polymorphism and chronic lymphocytic leukaemia

N. Mitsiades, C. Mitsiades, 2003, The Lancet.

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

K. Anderson, N. Munshi, P. Richardson, 2003, Cancer research.

HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes.

S. Hilsenbeck, C. Creighton, R. Lanz, 2016, Cancer research.

Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling

N. Mitsiades, C. Mitsiades, 2005, Expert review of anticancer therapy.

Molecular pathology of thyroid cancer: diagnostic and clinical implications.

N. Mitsiades, J. Fagin, 2008, Best practice & research. Clinical endocrinology & metabolism.

Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines.

N. Mitsiades, C. Mitsiades, V. Poulaki, 2003, The Journal of clinical endocrinology and metabolism.

Serum Adiponectin Concentrations and Tissue Expression of Adiponectin Receptors Are Reduced in Patients with Prostate Cancer: A Case Control Study

C. Mantzoros, N. Mitsiades, A. Giannopoulos, 2007, Cancer Epidemiology Biomarkers & Prevention.

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.

K. Anderson, P. Richardson, N. Mitsiades, 2005, Cancer research.

Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.

Joan W. Miller, N. Mitsiades, C. Mitsiades, 2005, Investigative ophthalmology & visual science.

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.

K. Anderson, N. Munshi, P. Richardson, 2003, Cancer research.

VEGF-dependent conjunctivalization of the corneal surface.

N. Mitsiades, B. Kirchhof, G. Yancopoulos, 2003, Investigative ophthalmology & visual science.

Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer

S. Larson, Jason S. Lewis, H. Lilja, 2018, Clinical Cancer Research.

Proteasome inhibitors as therapeutics.

P. Richardson, N. Mitsiades, C. Mitsiades, 2005, Essays in biochemistry.

Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors.

N. Mitsiades, V. Poulaki, M. Tsokos, 1999, Journal of the National Cancer Institute.

NF-kappa B as a therapeutic target in multiple myeloma.

N. Munshi, L. Dang, P. Richardson, 2002, The Journal of biological chemistry.

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.

N. Mitsiades, C. Mitsiades, S. Treon, 2002, Blood.

ligand-induced apoptosis in human multiple myeloma cells Intracellular regulation of tumor necrosis factor-related apoptosis-inducing

N. Mitsiades, C. Mitsiades, S. Treon, 2002 .

Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.

N. Mitsiades, C. Mitsiades, V. Poulaki, 2001, Cancer research.

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

N. Munshi, P. Richardson, N. Mitsiades, 2003, Oncogene.

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.

N. Munshi, P. Richardson, N. Mitsiades, 2004, Blood.

Caffeic Acid Phenethyl Ester Induces Leukocyte Apoptosis, Modulates Nuclear Factor-Kappa B and Suppresses Acute Inflammation

G. Chrousos, N. Mitsiades, M. Tsokos, 1999, Neuroimmunomodulation.

Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics

M. Ittmann, N. Mitsiades, Dallin Lowder, 2022, Cancer letters.

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.

N. Munshi, P. Richardson, N. Mitsiades, 2003, Cancer research.

Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies.

C. Mantzoros, N. Mitsiades, H. Moon, 2011, The Journal of clinical endocrinology and metabolism.

Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer

N. Mitsiades, D. Bedoya, 2012, Expert review of anticancer therapy.

ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells

K. Rajapakshe, C. Coarfa, V. Poulaki, 2018, Investigative ophthalmology & visual science.

Androgen receptor signalling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration sensitive prostate cancer.

N. Mitsiades, S. Kaochar, 2021, Endocrine-related cancer.

Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of 1-Integrin and Phosphatidylinositol 3-Kinase / AKT Signaling 1

N. Munshi, P. Richardson, N. Mitsiades, 2003 .

Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug

N. Mitsiades, C. Mitsiades, V. Poulaki, 2001, Expert opinion on investigational drugs.

Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase.

N. Mitsiades, V. Poulaki, M. Tsokos, 1998, The American journal of pathology.

Translational Protein Kinase C Inhibitors Sensitize GNAQ Mutant Uveal Melanoma Cells to Ionizing Radiation

Sean M. Hartig, M. Hamilton, S. McGuire, 2014 .

Receptor activator of nuclear factor-kappa B (RANK) ligand expression: In human multiple myeloma cells.

N. Munshi, P. Richardson, N. Mitsiades, 2001 .

The role of Fas and FasL as mediators of anticancer chemotherapy.

N. Mitsiades, C. Mitsiades, V. Poulaki, 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Immmunomodulatory Drug (Revamid) Co-stimulates T cells via The B7-CD28 pathway

N. Munshi, P. Richardson, N. Mitsiades, 2003 .

A T cell-binding fragment of fibrinogen can prevent autoimmunity.

N. Mitsiades, C. Mitsiades, Y. Takada, 2010, Journal of autoimmunity.

Novel biologically based therapies for Waldenstrom's macroglobulinemia.

P. Richardson, N. Mitsiades, C. Mitsiades, 2003, Seminars in oncology.

Title : HER 2 signaling drives DNA anabolism and proliferation through SRC-3 phosphorylation and E 2 F 1-regulated genes

S. Hilsenbeck, C. Creighton, R. Lanz, 2016 .

Thymoma-associated multiorgan autoimmunity: a graft-versus-host-like disease.

N. Mitsiades, P. Lara, M. Fung, 2007, Journal of the American Academy of Dermatology.

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

S. Hilsenbeck, R. Schiff, C. Coarfa, 2014, Cell Research.

β-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells

N. Munshi, N. Mitsiades, C. Mitsiades, 2002 .

Glucocorticoids mediate adverse events of deep androgen receptor axis inhibition in prostate cancer patients.

N. Mitsiades, S. Kaochar, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Fas/Fas ligand-associated apoptosis in experimental autoimmune uveoretinitis in rodents: role of proinflammatory corticotropin-releasing hormone.

G. Chrousos, N. Mitsiades, V. Poulaki, 2001, Experimental eye research.

A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis

Steven B. Neuhauser, Yvonne A. Evrard, Jeffrey H. Chuang, 2022, bioRxiv.

Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves' disease.

G. Chrousos, N. Mitsiades, V. Poulaki, 2000, Thyroid : official journal of the American Thyroid Association.

Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.

E. Kimby, N. Mitsiades, C. Mitsiades, 2003, Seminars in oncology.

LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma: Results of a pre-clinical evaluation in vitro and in vivo.

N. Munshi, P. Richardson, N. Mitsiades, 2002 .

Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases

G. Chrousos, N. Mitsiades, C. Mitsiades, 2001, Trends in Endocrinology & Metabolism.

The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer.

N. Mitsiades, C. Mitsiades, V. Poulaki, 2003, The Journal of endocrinology.

Heat shock protein-27 confers drug-resistance in multiple myeloma cells.

K. Anderson, P. Richardson, N. Mitsiades, 2002 .

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

T. Libermann, Marie G. Joseph, N. Mitsiades, 2004, Cancer cell.

Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.

K. Rajapakshe, C. Coarfa, N. Mitsiades, 2014, Cancer research.

Tumor and Stem Cell Biology AndrogenReceptor Is theKeyTranscriptionalMediator of the Tumor Suppressor SPOP in Prostate Cancer

K. Rajapakshe, C. Coarfa, N. Mitsiades, 2014 .

Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions

N. Mitsiades, D. Bedoya, 2013, OncoTargets and therapy.

Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction

I. Thompson, N. Agarwal, N. Mitsiades, 2017, JAMA oncology.

Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy.

N. Mitsiades, C. Mitsiades, A. Joussen, 2004, The American journal of pathology.

Activin a in the regulation of corneal neovascularization and vascular endothelial growth factor expression.

N. Mitsiades, B. Kirchhof, F. Kruse, 2004, The American journal of pathology.

Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies

N. Mitsiades, S. Treon, R. Schlossman, 2001, Journal of immunotherapy.

Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.

I. Stamenkovic, N. Mitsiades, W. Yu, 2001, Cancer research.

Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis.

N. Mitsiades, V. Poulaki, S. Tseleni-Balafouta, 1998, The Journal of clinical endocrinology and metabolism.

The Akt pathway: molecular targets for anti-cancer drug development.

Michael Koutsilieris, N. Mitsiades, C. Mitsiades, 2004, Current cancer drug targets.

Targeting BRAFV600E in thyroid carcinoma: therapeutic implications

D. McMillin, N. Mitsiades, C. Mitsiades, 2007, Molecular Cancer Therapeutics.

The essential role of GATA transcription factors in adult murine prostate

M. Ittmann, N. Mitsiades, Q. Feng, 2016, Oncotarget.

The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response

M. Loda, C. Coarfa, M. Freedman, 2022, Cancer research.

SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of cMYC oncoprotein

K. Rajapakshe, C. Coarfa, M. Ittmann, 2017, Oncogene.

Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.

C. Sander, N. Schultz, H. Scher, 2012, Cancer research.

Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.

Jinfang Zhang, Wenyi Wei, N. Mitsiades, 2017, Cancer letters.

Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover

M. Rubin, C. Coarfa, F. Demichelis, 2013, Proceedings of the National Academy of Sciences.

Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer

N. Mitsiades, C. Foley, Christopher Foley, 2016, Hormones and Cancer.

CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.

N. Munshi, N. Mitsiades, C. Mitsiades, 2003, Blood.

Inhibition of GATA2 in prostate cancer by a clinically available small molecule

K. Rajapakshe, C. Coarfa, N. Mitsiades, 2021, Endocrine-related cancer.

GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex

S. Hilsenbeck, Sean M. Hartig, K. Rajapakshe, 2014, Proceedings of the National Academy of Sciences.

Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.

N. Mitsiades, V. Poulaki, S. A. Chew, 2011, Investigative ophthalmology & visual science.

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions.

N. Munshi, P. Richardson, N. Mitsiades, 2006, European journal of cancer.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Yvonne A. Evrard, Michael W. Lloyd, Jeffrey H. Chuang, 2021, Nature Genetics.

Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.

N. Munshi, N. Mitsiades, C. Mitsiades, 2003, Blood.

Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2.

N. Mitsiades, V. Poulaki, M. Tsokos, 2001, Cancer research.

Protein and bcl-2 Mitochondrial Activation and Is Inhibited by FLICE Inhibitor Fas-mediated Apoptosis in Neuroblastoma Requires

N. Mitsiades, V. Poulaki, M. Tsokos, 2001 .

Correction: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer.

K. Rajapakshe, C. Coarfa, N. Mitsiades, 2019, Cancer research.

Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer

K. Rajapakshe, C. Coarfa, B. O’Malley, 2016, Oncogene.

A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.

N. Mitsiades, 2013, Cancer research.

Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

Masaharu Akiyama, P. Richardson, N. Mitsiades, 2002, Oncogene.

JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells*

N. Munshi, N. Mitsiades, C. Mitsiades, 2003, The Journal of Biological Chemistry.

B-Raf Inhibition in the Clinic: Present and Future.

N. Mitsiades, W. Fiskus, 2016, Annual review of medicine.

Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment

N. Munshi, P. Richardson, N. Mitsiades, 2007, Journal of cellular biochemistry.

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.

Marie Joseph, Masaharu Akiyama, T. Libermann, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Identification of genes modulated in multiple myeloma using genetically identical twin samples.

D. Carrasco, D. Auclair, R. Fonseca, 2004, Blood.

Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer

Eric A. Smith, Sean M. Hartig, K. Rajapakshe, 2018, Nature Metabolism.

Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer

Eric A. Smith, Sean M. Hartig, K. Rajapakshe, 2018, Nature Metabolism.

Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis.

A. Chinnaiyan, K. Rajapakshe, C. Coarfa, 2015, The Journal of clinical investigation.

therapeutic applications B blockade in multiple myeloma: κ - Biologic sequelae of nuclear factor

N. Munshi, N. Mitsiades, C. Mitsiades, 2013 .

Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability.

N. Mitsiades, B. Kirchhof, C. Mitsiades, 2002, The American journal of pathology.

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.

N. Munshi, P. Richardson, N. Mitsiades, 2002, Blood.

Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.

D. McMillin, Jake E. Delmore, N. Mitsiades, 2007, The Journal of clinical endocrinology and metabolism.

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).

N. Munshi, P. Richardson, P. Tassone, 2004, Blood.

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

T. Libermann, N. Munshi, Marie G. Joseph, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer

N. Mitsiades, S. Kaochar, 2021 .

The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.

Joseph Negri, Joan W. Miller, D. McMillin, 2007, Investigative ophthalmology & visual science.

Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.

D. McMillin, N. Mitsiades, C. Mitsiades, 2006, The Journal of clinical endocrinology and metabolism.

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

P. Richardson, N. Mitsiades, C. Mitsiades, 2001, Blood.

CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications

N. Mitsiades, C. Mitsiades, Y. Shima, 2002, Journal of immunotherapy.

Multimodal action of ONECUT2 in driving neuroendocrine prostate cancer

N. Mitsiades, S. Kaochar, 2019, Translational cancer research.

Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib

N. Munshi, D. McMillin, P. Richardson, 2009, Clinical Cancer Research.

NF-κB as a Therapeutic Target in Multiple Myeloma*

N. Munshi, L. Dang, P. Richardson, 2002, The Journal of Biological Chemistry.

Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells*

G. Morgan, N. Munshi, N. Mitsiades, 2003, The Journal of Biological Chemistry.

Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment

A. Culhane, N. Mitsiades, I. Georgakoudi, 2020, Cancer Research.

Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.

Robert M Hoffman, N. Munshi, N. Mitsiades, 2003, Cancer research.

Focus on multiple myeloma.

N. Munshi, N. Mitsiades, C. Mitsiades, 2004, Cancer cell.

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.

N. Munshi, P. Richardson, N. Mitsiades, 2002, Blood.

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.

Gonzalez, W. Wong, G. Morgan, 2003, Blood.

Genomic landscape of advanced prostate cancer in racial minority populations: Real-world experience in a safety-net hospital oncology clinic.

N. Mitsiades, Heidi Dowst, M. Mims, 2021 .

Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.

R. Schiff, C. Coarfa, N. Mitsiades, 2020, Journal of medicinal chemistry.

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.

W. Wong, D. Auclair, N. Munshi, 2003, Blood.

Proteasome inhibition as a therapeutic strategy for hematologic malignancies

P. Richardson, N. Mitsiades, C. Mitsiades, 2005, Expert review of anticancer therapy.

Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.

Sean M. Hartig, S. McGuire, N. Mitsiades, 2014, Investigative ophthalmology & visual science.

Fas Signaling in Thyroid Carcinomas Is Diverted from Apoptosis to Proliferation

D. McMillin, N. Mitsiades, C. Mitsiades, 2006, Clinical Cancer Research.

The Gem GTP-binding protein promotes morphological differentiation in neuroblastoma

V. Poulaki, N. Mitsiades, Y. Ward, 2001, Oncogene.

Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.

N. Mitsiades, S. Treon, R. Schlossman, 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.

N. Mitsiades, V. Poulaki, S. Tseleni-Balafouta, 1999, The Journal of clinical endocrinology and metabolism.

Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias

N. Mitsiades, C. Mitsiades, S. Treon, 2001, Expert opinion on investigational drugs.

Antimyeloma activity of heat shock protein-90 inhibition.

T. Libermann, G. Morgan, N. Munshi, 2005, Blood.

Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I in Thyroid Carcinomas

N. Mitsiades, C. Mitsiades, V. Poulaki, 2003 .

The FASEB Journal express article 10.1096/fj.02-0157fje. Published online November 15, 2002. Suppression of Fas-FasL-induced endothelial cell apoptosis

Bernd Kirchhof, N. Mitsiades, B. Kirchhof, 2022 .

Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors.

C. Mantzoros, A. Wolk, N. Mitsiades, 2008, Endocrine-related cancer.

Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study

C. Mantzoros, N. Mitsiades, S. Tseleni-Balafouta, 2009, Cancer Causes & Control.

Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.

Bernd Kirchhof, John Rudge, N. Mitsiades, 2002, The American journal of pathology.

Molecular sequelae of histone deacetylase inhibition in human malignant B cells.

N. Munshi, P. Richardson, P. Marks, 2003, Blood.

Molecular Genetics of Thyroid Cancer: Pathogenetic Significance and Clinical Applications

N. Mitsiades, J. Fagin, 2010 .

Nonsteroidal anti‐inflammatory drugs prevent early diabetic retinopathy via TNF‐α suppression

Bernd Kirchhof, N. Mitsiades, B. Kirchhof, 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.

Joan W. Miller, P. Marks, N. Mitsiades, 2009, Investigative ophthalmology & visual science.

Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer

P. Marks, N. Mitsiades, C. Mitsiades, 2005, Clinical Cancer Research.

Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer

Ali Shojaie, Katrin Panzitt, Fabio Stossi, 2016, Nature Communications.

A Novel Mechanism to Drive Castration-Resistant Prostate Cancer

N. Mitsiades, S. Kaochar, 2018, Trends in endocrinology and metabolism.

Proteasome inhibitors as therapeutics: Figure 1

P. Richardson, N. Mitsiades, C. Mitsiades, 2005 .

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.

N. Munshi, P. Richardson, N. Mitsiades, 2008, Cancer research.

CC-5013 (Celgene).

N. Mitsiades, C. Mitsiades, 2004, Current opinion in investigational drugs.

Avicins: A Novel Class of Anti-Myeloma Agents.

N. Munshi, N. Mitsiades, C. Mitsiades, 2004 .

In vitro anti‐myeloma activity of the Aurora kinase inhibitor VE‐465

D. McMillin, Jake E. Delmore, P. Richardson, 2009, British journal of haematology.

Activity of New Heat Shock Protein 90 (hsp90) Inhibitor NVP-AUY922 Against Myeloma Cells Sensitive and Resistant to Conventional Agents.

N. Munshi, D. McMillin, Jake E. Delmore, 2007 .

Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).

N. Munshi, P. Richardson, N. Mitsiades, 2004 .

beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.

N. Munshi, N. Mitsiades, D. Chauhan, 2002, Experimental hematology.

Skin Manifestations of Cushing Disease in Children and Adolescents Before and After the Resolution of Hypercortisolemia

G. Chrousos, N. Mitsiades, C. Mitsiades, 1998, Pediatric dermatology.

IGF-II is a major proliferative/anti-apoptotic cytokine and a therapeutic target in multiple myeloma, other hematologic neoplasias and solid tumors.

N. Mitsiades, C. Mitsiades, A. Kung, 2004 .

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of b1-integrin and phosphatidylinositol 3-kinase/AKT signaling beta.

N. Munshi, P. Richardson, N. Mitsiades, 2003 .

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer

Adrian V. Lee, Purba Singh, A. Han, 2021, Cancer Research.

Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.

N. Mitsiades, C. Mitsiades, G. Voutsinas, 2006, The Journal of clinical endocrinology and metabolism.

Proteasome inhibition as a new therapeutic principle in hematological malignancies.

P. Richardson, N. Mitsiades, C. Mitsiades, 2006, Current drug targets.

Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies.

C. Mantzoros, N. Mitsiades, T. Kelesidis, 2007, The Journal of clinical endocrinology and metabolism.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Steven B. Neuhauser, Yvonne A. Evrard, Michael W. Lloyd, 2019, Nature Genetics.

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery

Yvonne A. Evrard, David M. Rocke, Jessica J. Andrews, 2022, NAR cancer.

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery

Steven B. Neuhauser, Yvonne A. Evrard, Michael W. Lloyd, 2021, bioRxiv.

CD 40 induces human multiple myeloma cell migration via phosphatidylinositol 3 – kinase / AKT / NF-B signaling

N. Munshi, N. Mitsiades, C. Mitsiades, 2003 .

The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo.

N. Munshi, H. Lane, P. Richardson, 2004 .

Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside.

F. Prósper, J. Miguel, N. Munshi, 2007 .

Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias.

N. Mitsiades, C. Mitsiades, S. Treon, 2003, Seminars in oncology.

Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.

K. Rajapakshe, C. Coarfa, N. Mitsiades, 2014, Cancer research.

Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors.

C. Mantzoros, A. Wolk, N. Mitsiades, 2008, Endocrine-related cancer.

Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.

Joan W. Miller, P. Marks, N. Mitsiades, 2009, Investigative ophthalmology & visual science.

Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma.

N. Munshi, P. Richardson, N. Mitsiades, 2005 .

Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report.

N. Mitsiades, A. Doufas, D. Koutras, 1997, Thyroid : official journal of the American Thyroid Association.

In vitro anti‐myeloma activity of the Aurora kinase inhibitor VE‐465

Jake E. Delmore, P. Richardson, N. Mitsiades, 2009, British journal of haematology.